BTC CLASS OF DRUGS UNDER STUDY AT FDA

MAY 01, 2007

A new class of drugs—sandwiched between prescription and OTC medications and available only from pharmacists—is under active consideration by top FDA regulators. Word of the FDA's interest in the proposed new "behind-the-counter"(BTC) class of drugs surfaced during an address by FDA Pharmacy Affairs Director Ilisa B.G. Bernstein, PharmD, JD, at the American Pharmacists Association's (APhA) Annual Meeting in Atlanta, Ga.

Although critics of a new third class of drugs contend that limiting these medicines to sale in pharmacies would restrict consumer access to medication, FDA officials insist that their BTC plan would have just the opposite effect. According to Dr. Bernstein, the goal of the plan is to increase patient access to certain medicines that would otherwise require a prescription.

APhA—a longtime advocate of a pharmacist-only third class of drugs—welcomed the FDA's interest in the plan and predicted that patients would benefit from the change.

A number of other countries already have a pharmacist-only third class of drugs, but creating such a system in the United States would require action by Congress as well as the FDA.

For a related article, visit ePharmacy Times at www.pharmacytimes.com/article Newsletter.cfm?ID=4511.




SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.